Biological Chemistry · 2018 · 32 citations · 27 references
MedicineNuclear MedicinePharmacokineticsMolecular ImagingNanomaterialsTherapeutic Nuclear MedicineNanomedicinePharmacokinetics Of Monoclonal AntibodiesTargeted Imaging AgentsBiodistribution StudiesIn Vivo StudiesMolecular Imaging TracersNanobodiesRadioactive TracersRadionuclide TracersTargeted Molecular Imaging AgentsTracer Specific Activity
Let's parse content. Background: "Abstract Radiolabeling of nanobodies with radiometals by chelation has the advantage of being simple, fast and easy to implement in clinical routine." So background: radiolabeling of nanobodies with radiometals by chelation is simple, fast, easy for clinical routine. Purpose: lines labeled Purpose: first line: "In this study, we validated 68 Ga/ 111 In-labeled anti-VCAM-1 nanobodies as potential radiometal-based tracers for molecular imaging of atherosclerosis." Also second Purpose: "We further investigated the impact of different radiolabeling strategies on the in vivo biodistribution of nanobody-based tracers." So purpose: validate 68Ga/111In anti-VCAM-1 nanobodies as tracers for atherosclerosis imaging and investigate impact of radiolabeling strategies on biodistribution. Mechanism: lines labeled Mechanism: same as Purpose lines.
Abstract Radiolabeling of nanobodies with radiometals by chelation has the advantage of being simple, fast and easy to implement in clinical routine. In this study, we validated 68 Ga/ 111 In-labeled anti-VCAM-1 nanobodies as potential radiometal-based tracers for molecular imaging of atherosclerosis. Both showed specific targeting of atherosclerotic lesions in ApoE −/− mice. Nevertheless, uptake in lesions and constitutively VCAM-1 expressing organs was lower than previously reported for the 99m Tc-labeled analog. We further investigated the impact of different radiolabeling strategies on the in vivo biodistribution of nanobody-based tracers. Comparison of the pharmacokinetics between 68 Ga-, 18 F-, 111 In- and 99m Tc-labeled anti-VCAM-1 nanobodies showed highest specific uptake for 99m Tc-nanobody at all time-points, followed by the 68 Ga-, 111 In- and 18 F-labeled tracer. No correlation was found with the estimated number of radioisotopes per nanobody, and mimicking specific activity of other radiolabeling methods did not result in an analogous biodistribution. We also demonstrated specificity of the tracer using mice with a VCAM-1 knocked-down phenotype, while showing for the first time the in vivo visualization of a protein knock-down using intrabodies. Conclusively, the chosen radiochemistry does have an important impact on the biodistribution of nanobodies, in particular on the specific targeting, but differences are not purely due to the tracer’s specific activity.
27
Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer
Ilse Vaneycken, Nick Devoogdt, Naomi Van Gassen et al. · The FASEB Journal · 2011 · 312 citations
Medicine, Oncology, Pharmacology +17
Catarina Xavier, Ilse Vaneycken, Matthias D’Huyvetter et al. · Journal of Nuclear Medicine · 2013 · 223 citations · Full text
Medicine, Oncology, Pharmacology +17
Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions
Alexis Broisat, Sophie Hernot, Jakub Toczek et al. · Circulation Research · 2012 · 195 citations · Full text
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Matthias D’Huyvetter, Jens De Vos, Catarina Xavier et al. · Clinical Cancer Research · 2017 · 180 citations · Full text
Medicine, Nuclear Medicine, Oncology +17